Oppenheimer on Veru, Inc. (VERU): 'expect sabizabulin to be granted Emergency Use Authorization in the weeks following the ad comm'
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $36.00 price target on Veru, Inc. (NASDAQ: VERU).The analyst comments "Briefing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
